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the CC BY-NC-ND license (http://creaAbstract Objective: To examine the prognostic value of tumor major histocompatibility
complex I (MHCI) expression on survival and recurrence in patients with clear cell renal cell
carcinoma (RCC).
Methods: Fifty-three patients that underwent nephrectomy at our institution for clear cell RCC
(T1eT3) with 4 years of follow-up were queried from our nephrectomy database. Immunohis-
tochemical staining for MHCI was performed on tumor specimens and MHCI expression was
quantified with an automated image analysis technique. Patients were divided into high and
low MHCI expression groups in order to study the relationship between MHCI expression and
prognosis using the KaplaneMeier method and log-rank test.
Results: Overall survival and recurrence free survival were increased in the high MHCI expres-
sion group compared to the low MHCI expression group (log-rank, p Z 0.036 and p Z 0.028,
respectively). Patients alive at the end of the study had higher MHCI expression (mean positiv-
ity score 0.82) than those that died of disease (mean positivity score 0.76, t test, p Z 0.030).
Patients that did not develop recurrence during the study period had higher MHCI expression
(mean positivity score 0.83) than those that did develop recurrence (mean positivity score
0.78), but this difference was not significant (t test, p Z 0.079).u (V.A. Master).
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recurrence free survival in patients with clear cell RCC and could serve as an important prog-
nostic tool in identifying high-risk patients.
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With a growing incidence over the past decades, renal cell
carcinoma (RCC) afflicts the lives of almost 64 000 patients
and claims approximately 13 500 lives annually in the
United States [1]. Of these cases, two-thirds have localized
disease on initial presentation with potential for curative
nephrectomy. However, despite prognostic tools such as
TNM staging and Fuhrman Nuclear Grade (FNG), accurate
assessment of prognosis post-nephrectomy remains inade-
quate with one-third of these patients developing metas-
tases and eventually succumbing to disease [2e5]. Further,
a recent validation study of the TNM staging system for
RCC showed overlapping prognoses between TNM substages
as well as insufficient ability to differentiate high-risk
disease [6]. Accordingly, more rigorous indicators for dis-
ease progression and recurrence are required to effec-
tively stratify patients to determine appropriate modes of
treatment and surveillance, and potentially for accrual
into clinical trials.
With recent advancements in cancer immunology, the
immune system has been well established as an integral
factor in tumor progression in various malignancies, but a
better understanding of the host anti-tumor immune
response is still needed to identify molecular markers able
to predict prognosis and survival [7,8]. Characterizing the
intratumoral immune microenvironment into an “immuno-
score” has been shown to be an effective tool to assess
prognosis, even outperforming traditional histopathological
tools in patients with colorectal cancer [9e11]. In RCC,
mechanisms for tumor immune evasion of cytotoxic T
lymphocytes (CTLs) have been studied [12]. Major histo-
compatibility complex class I (MHCI) expression plays a
critical role in tumor antigen recognition and CTL activa-
tion, thus it is no surprise that loss of tumor cell MHCI
expression has been associated with worse outcomes in RCC
[12e14]. In an investigation of MHCI expression in RCC,
Kitamura et al. [12] and Yuan et al. [15] found that patients
with downregulated MHCI expression had decreased
recurrence-free survival. Further studies have also shown
that decreased tumor MHCI expression is associated with
larger tumor size and increased metastatic potential [13].
These findings suggest that MHCI expression could serve as a
prognostic marker to better characterize disease progres-
sion and recurrence.
Though recent studies have evaluated the role of the
host immune response in cancer progression, the utiliza-
tion of immunologic biomarkers for postoperative surveil-
lance in patients with RCC has yet to be fully explored. In
a previous study evaluating 34 RCC patients with auto-
mated image analysis, we found that higher tumor MHCIexpression can help predict survival after nephrectomy
and even after recurrence [14]. In this study, we continue
to investigate tumor MHCI expression as a prognostic tool
in a larger cohort and over an increased follow-up
interval.
2. Patients and methods
2.1. Patient selection
Our Nephrectomy Database was queried for patient selec-
tion. Inclusion criteria were a history of localized clear cell
RCC at presentation and at the time of nephrectomy, and at
least 4 years of clinical follow-up information without loss to
follow-up. Patients that died of their disease prior to 4 years
were still included in the study. All cases were pathologi-
cally confirmed by a fellowship trained Urologic Pathologist
to be clear cell RCC and were graded and staged according
to current guidelines. Patients with T4 disease, clinically
suspicious or pathologically confirmed nodal disease, or
metastatic disease on presentation were excluded. Subjects
that died during the follow-up period due to causes unre-
lated to RCC and patients that received immunotherapy
were excluded from the study. Patients under the age of
18 years were excluded as well.
The follow-up period was the interval between ne-
phrectomy and the subject’s most recent follow-up status.
Follow-up information on each subject was obtained
retrospectively in the electronic medical records, the Na-
tional Death Index, the Social Security Death Index, or by
calling the patients’ primary care physicians or other
medical providers; or the patients/families themselves
were contacted if necessary. All subjects that developed
metastases underwent tyrosine kinase inhibitor treatment
according to standard of care. Our Institutional Review
Board approved the study.
2.2. Immunohistochemistry (IHC)
Paraffin-embedded tissue blocks containing both tumor and
adjacent normal kidney parenchyma were used. Normal
parenchyma in each sample was stained and observed to
account for batch variation. No difference in staining in-
tensity of normal parenchyma was observed between
samples. The IHC stainings were performed with an MHCI
antibody (clone EMR 8-5; Abcam, Cambridge, UK) following
the previously described protocol used at our institution
[16]. The obtained slides were then captured on a Nikon
Eclipse E400 microscope (Nikon, Tokyo, Japan) using SPOT
Flex 15.2 64 Mp Shifting Pixel Camera and SPOT software
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2.3. Automated image and statistical analyses
The digital images were then analyzed with the Aperio
image analysis software (Leica Biosystems, Wetzlar, Ger-
many) for quantification of MHCI expression using a previ-
ously validated method with modifications [17]. The
positive pixel count (PPC) is an algorithm of the Aperio
image analysis software that provides the absolute number
of pixels positive for the MHCI staining in a pre-determined
area divided by the total number of pixels (meaning all the
positive and the negative pixels) in the analyzed area. The
obtained numerical value is called the “positivity score”
and it quantifies MHCI expression. Positive pixels were
determined with the parameters of the PPC algorithm
including color (of the antibody’s staining) and minimal and
maximal intensity (the brightness of the staining). Five
boxes of 2500 pixels by 2500 pixels were selected in
representative areas of tumor and the PPC algorithm was
applied to these boxes. The same process was repeated for
the adjacent normal kidney parenchyma. Patients were
divided into high and low MHCI expression groups in order to
study the relationship between MHCI expression and prog-
nosis using the KaplaneMeier method and log-rank test.
Student’s t test, ANOVA, ManteleCox test or non-
parametric KruskaleWallis test were all conducted as
indicated in the text. Statistical analyses were performed
with JMP 12 (SAS, Cary, NC, USA). Univariate and multi-
variate Cox proportional survival analysis was performed
with SAS (SAS, Cary, NC, USA).Table 1 Patient demographics.
Parameter
Alive without
disease (n Z 25)
Ali
dis
Age at intervention (year)a 59.5  11.3 62.
Genderb
Female 14 (56.0) 4
Male 11 (44.0) 7
Raceb
African American 3 (12.0) 0
American Indian 1 (4.0) 0
Asian 1 (4.0) 1
Caucasian 19 (76.0) 10
Hispanic 1 (4.0) 0
Stageb
T1 11 (44.0) 2
T2 7 (28.0) 4
T3 7 (28.0) 5
FNGb
2 14 (56.0) 4
3 11 (44.0) 5
4 0 (0.0) 2
FNG, Fuhrman nuclear grade.
a Values are presented as mean  SD.
b Values are presented as n (%).3. Results
3.1. Cohort description
Fifty-three patients comprised the study cohort, which is
described in Table 1. Mean age at the beginning of the study
was 62.5 years (range 35e89 years). Tumor stages were
evenly distributed within the cohort with 18/53 (34.0%) pa-
tients with stage T1 cancer, 14/53 (26.4%) with stage T2, and
21/53 (39.6%) with stage T3. However, FNGs were unevenly
distributed within the cohort with 19/53 (35.8%) patients
with FNG 2, 26/53 (49.1%) with FNG 3, and 8/53 (15.1%) with
FNG 4. Of note, a fellowship-trained pathologist changed the
FNG of four patients from 3 to 4 on review. The subjects were
followed after nephrectomy as described in the methods
section, and mean and median clinical follow-up was 73.3
and 63 months respectively (range: 3e225 months, nZ 53).
Of the study cohort, 36/53 (67.9%) subjects were alive and
17/53 (32.1%) deceased due to clear cell RCC at the end of
the study. Further, 28/53 (52.9%) patients developed me-
tastases during the study, of which 17/28 (60.7%) succumbed
to their disease. The remaining 25/53 (47.1%) patients were
alive at the end of the study and had no radiographic or
clinical evidence of recurrence (Table 2).
3.2. Automated positive pixel counting on IHC to
assess MHCI expression
In this study we used the automated PPC algorithm of the
Aperio software to assess the degree of MHCI expression in
each tumor slide. The numerical value obtained was called
the “positivity score”, the ratio of positively stained pixelsOutcome
ve with
ease (n Z 11)
Dead with
disease (n Z 17)
All
(n Z 53)
1  11.3 67.2  13.9 62.5  12.5
(36.4) 6 (35.3) 24 (45.3)
(63.6) 11 (64.7) 29 (54.7)
(0.0) 4 (23.5) 7 (13.2)
(0.0) 0 (0.0) 1 (1.9)
(9.1) 0 (0.0) 2 (3.8)
(90.9) 13 (76.5) 42 (79.2)
(0.0) 0 (0.0) 1 (1.9)
(18.2) 5 (29.4) 18 (34.0)
(36.4) 3 (17.6) 14 (26.4)
(45.4) 9 (53.0) 21 (39.6)
(36.4) 1 (5.9) 19 (35.8)
(45.4) 10 (58.8) 26 (49.1)
(18.2) 6 (35.3) 8 (15.1)
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total amount of pixels analyzed, allowing objective quan-
titation of MHCI expression with IHC. Visually, antibody
staining (brown) was localized to tumor cell membranes
and diffusely distributed throughout the specimen. The
tumor MHCI positivity score for the entire cohort was
0.80  0.01 (mean  SE, n Z 53) and median MHCI
expression was 0.81 (range 0.40e0.92). The normal kidney
parenchyma MHCI positivity score for the entire cohort was
0.46  0.02 (mean  SE, n Z 53) and median MHCI
expression was 0.47 (range 0.06e0.71). Mean MHCI
expression was significantly higher in tumor than in normal
kidney parenchyma (t test, p < 0.0001). To investigate the
impact of MHCI on patient prognosis, the subjects were
categorized, according to tumor MHCI positivity score, into
the low (below the mean of 0.80) MHCI expression group or
the high (above the mean of 0.80) MHCI expression group.
Of the study cohort, 22/53 (41.5%) patients had low MHCI
expression and 31/53 (58.5%) had high expression as seen in
Table 2.
3.3. High MHCI expression is associated with
improved survival and decreased recurrence
Mean MHCI positivity score for the “alive” subgroup (pos-
itivity score 0.82  0.02 (mean  SE), n Z 36) was
significantly higher than in the “deceased” subgroup
(positivity score 0.76  0.02 (mean  SE), n Z 17, t test,
p Z 0.030). To further evaluate the effect of MHCI
expression on patient survival, overall survival was
compared in the high (above the mean of 0.80) vs. low
(below the mean of 0.80) MHCI expression groups. Time-to-
death was significantly longer in the high MHCI expression
group (log-rank, pZ 0.036; Fig. 1A). Median time-to-death
for censored and non-censored subjects was 78.7 months
and 28.4 months, respectively. Further, only 6/31 (19.4%)Table 2 High vs. low MHCI expression.
Parameter
Low MHCI
(n Z 22)
Stagea
T1 4 (18.2)
T2 7 (31.8)
T3 11 (50.0)
FNGa
2 7 (31.8)
3 10 (45.5)
4 5 (22.7)
Outcomea
Alive without disease 7 (31.8)
Alive with disease 4 (18.2)
Dead with disease 11 (50.0)
Tumor positivityb 0.7  0.1
MHCI, major histocompatibility complex I.
a Values are presented as n (%).
b Values are presented as mean  SD.subject deaths occurred in the group of patients with high
MHCI scores while 11/22 (50.0%) subjects of the low MHCI
group died (Table 2). Univariate analysis showed that MHCI
expression and FNG were significant factors influencing
overall survival (log-rank, p Z 0.036 and p < 0.001,
respectively), however TNM stage was not (log-rank,
p Z 0.440). In multivariate analysis, only FNG was a sig-
nificant and independent factor influencing overall survival
(p Z 0.028).
Decreased MHCI expression also correlated with the
development of metastases post-nephrectomy. Mean MHCI
positivity score of the subjects that did not recur
(0.83  0.02 (mean  SE), n Z 25) during the study was
higher than the mean MHCI positivity score of those that
did recur (0.78  0.02 (mean  SE), n Z 28), but this
difference was not significant (t test, p Z 0.079).
Furthermore, time-to-recurrence was longer in patients in
the high MHCI expression group (log-rank, p Z 0.028;
Fig. 1B). Median time-to-recurrence for censored and non-
censored subjects was 74.0 months and 11.3 months,
respectively. In the low MHCI group, 15/22 (68.2%) subjects
recurred within the follow-up time, while only 13/31
(41.9%) subjects developed metastases in the high MHCI
group (Table 2). Univariate analysis showed that MHCI
expression and FNG were significant factors influencing
recurrence-free survival (log-rank, p Z 0.028 and
p < 0.001, respectively). In multivariate analysis, only FNG
was a significant and independent factor influencing
recurrence-free survival (p Z 0.035).
Finally, to compare MHCI expression with commonly
used prognostic tools in the clinical setting, the mean MHCI
scores of subjects with FNG 2, 3 and 4, and stages T1, T2
and T3 were compared (Table 3). No collinearity was found
between FNG and tumor MHCI expression (ANOVA,
F Z 0.12, p Z 0.88) or between stage at presentation and
tumor MHCI expression (ANOVA, F Z 0.39, p Z 0.68).High vs. low MHCI expression
High MHCI
(n Z 31)
All
(n Z 53)
14 (45.2) 18 (34.0)
7 (22.6) 14 (26.4)
10 (32.2) 21 (39.6)
12 (38.7) 19 (35.8)
16 (51.6) 26 (49.1)
3 (9.7) 8 (15.1)
18 (58.0) 25 (47.1)
7 (22.6) 11 (20.8)
6 (19.4) 17 (32.1)
0.9  0.0 0.8  0.1
Table 3 MHCI expression (mean  SD).
Outcome
Alive without
disease
Alive with
disease
Dead with
disease
All
All 0.83  0.07 0.81  0.09 0.76  0.12 0.80  0.10
Stage
T1 0.81  0.08 0.87  0.06 0.81  0.10 0.81  0.08
T2 0.82  0.10 0.83  0.07 0.63  0.20 0.78  0.14
T3 0.86  0.03 0.77  0.10 0.77  0.08 0.80  0.08
FNG
2 0.80  0.09 0.80  0.04 0.81  0.04 0.80  0.08
3 0.86  0.04 0.81  0.13 0.74  0.14 0.81  0.12
4 N/A 0.82  0.06 0.77  0.10 0.78  0.09
FNG, fuhrman nuclear grade; MHCI, major histocompatibility
complex class I.
Figure 1 High MHCI expression is associated with increased survival and decreased recurrence. (A) Increased survival seen in
patients with high MHCI expression; (B) Increased time until recurrence in patients with high MHCI. MHCI, major histocompatibility
complex class I.
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In this study we show that MHCI expression varies widely in
patients with clear cell RCC and that upregulation of tumor
MHCI expression is associated with increased overall sur-
vival and recurrence-free survival post-nephrectomy.
Further, patients that survived at the end of the study
had a significantly higher mean MHCI positivity score
compared to those who died from their disease. Similarly,
those who did not have recurrence at the end of the study
had a higher mean MHCI positivity score compared to those
who developed metastatic disease, however this difference
was not statistically significant. Together, these data sug-
gest that MHCI expression could serve as a powerful prog-
nostic tool capable of differentiating high-risk disease and
help direct post-operative care in patients with clear cell
RCC.
Our study also evaluated the relationship between MHCI
expression on tumor characteristics, including TNM stage
80 R.R. Sekar et al.and FNG. Consistent with previous results, our data show no
collinearity between MHCI expression, FNG, and TNM
staging. These findings demonstrate that MHCI expression
influences cancer pathogenesis independent of FNG and
TNM stage, suggesting that effective immune recognition of
RCC by the host immune system plays a critical role in
disease progression that might not otherwise be captured
by traditional histopathological prognostic tools.
Several studies have looked into the role of MHCI
expression in patients with RCC as well as other malig-
nancies. Brasnac et al. [13] first reported that approxi-
mately 15% of patients with RCC had down regulation of
HLA class I and that this pattern was associated with
increased tumor size and advanced tumor stage. These
findings were later confirmed by Atkins et al. [20] who went
on to propose down regulation of HLA class I expression as
an immune escape mechanism. With Japanese and Chinese
cohorts, subsequent studies have found that down-
regulation of tumor MHCI expression is associated with
decreased survival [12,15]. With an American cohort con-
sisting of mainly Caucasians and African Americans, we
confirm these previous findings and expand upon a previous
study by our group with a larger sample size and increased
follow-up period.
The improved prognosis with MHCI upregulation in our
cohort could be explained via modulation of the tumor im-
mune microenvironment with increased infiltration of CTLs.
The exact role of MHCI expression in tumor immune evasion
and RCC progression has yet to be further studied. Previous
studies have shown that tumor cell growth and MHCI
expression are closely linked by shared gene activation
pathways [17,18]. In addition, others have found that certain
MHCI haplotypes and differential expression of MCHI asso-
ciated antigen processing molecules in RCC tumor tissue al-
lows for immune escape and disease progression [19,20]. The
therapeutic potential of targeted immunotherapies used in
RCC and in other solid organ malignancies is another argu-
ment for using MHCI expression quantification and other
immune scoring systems [21,22]. In fact, conventional
chemotherapy and targeted therapies in advanced RCC have
other relevant immune effects and could have an effect on
MHCI expression, further underlying the need for immune
biomarkers [23,24].
It is important to note that in contrast to the previous
study by Kitamura et al. [12], we found that MHCI
expression was not an independent and significant pre-
dictor of overall survival or recurrence free survival in
multivariate analysis. This difference could be due to
several factors such as our exclusion criteria of patients
with T4 disease as well as genetic and racial differences
between our patient populations. Despite this finding,
MHCI expression still provides crucial information in the
management of patients with RCC in adjunct with other
prognostic tools. While TNM stage and FNG characterize
tumor aggressiveness, MHCI expression is a marker of the
antigen processing and presentation machinery within
tumor cells. With the expanding use of immune checkpoint
blockade, neoantigen based therapeutics, and other im-
munotherapies that hinge on the effector function of CTLs,
developing a detailed understanding of tumor cell antigen
processing and presentation will become increasingly
important.The findings of this study suggest that MHCI could be a
potent prognostic tool in patients with RCC after undergo-
ing nephrectomy. In addition, the automated image anal-
ysis technique used in this study allowed for objective
quantification of MHCI tumor expression, differing from the
pathologist-dependent semi-quantitative technique used in
previous studies [12,15]. In fact, an automated pixel count
of MHCI IHC staining could be an ideal technique for the
larger multi-center prospective studies that are needed to
determine if MHCI is a practical clinical biomarker to pre-
dict survival in RCC.
5. Conclusion
Our data demonstrate that upregulation of MHCI expression
on tumor cells confers improved overall survival and
recurrence-free survival in patients undergoing nephrec-
tomy for localized clear cell RCC. Therefore, MHCI
expression could serve as an important prognostic tool in
differentiating patients with high-risk disease and deter-
mining appropriate modes of post-operative management.
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